Physician

Adli Yakan, MD

According to 2025 Medicare claims, Adli Yakan, MD (NPI: 1417174699) practices hematology/oncology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Macomb, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 48066-5821.

Yakan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 668 traditional Medicare patients, billed 113,611 HCPCS/CPT codes, and received $2,452,385 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,739 prescription claims across 406 beneficiaries totaling $4,638,431 in drug costs, led by Brukinsa (Zanubrutinib). 2022 DME data shows 26 claims. Open Payments data shows 26 records totaling $513. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,253,429 to $2,452,385. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,148,449 to $4,638,431. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,597 to $1,262.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.5M$3.0M2015 Medicare payment: $1,253,429 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,516,177 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,618,034 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,883,181 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,619,866 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,752,288 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,121,233 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,688,616 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $3,034,814 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,452,385 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015648125,860$1,253,429
2016667157,520$1,516,177
2017740188,370$1,618,034
2018819180,975$1,883,181
2019811198,537$2,619,866
2020719234,628$2,752,288
2021702214,246$2,121,233
2022758234,519$2,688,616
2023742183,013$3,034,814
2024668113,611$2,452,385

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$2.8M$5.7M2015 Drug cost: $1,148,449 (USD; Tot_Drug_Cst)2016 Drug cost: $1,294,338 (USD; Tot_Drug_Cst)2017 Drug cost: $1,715,738 (USD; Tot_Drug_Cst)2018 Drug cost: $2,356,908 (USD; Tot_Drug_Cst)2019 Drug cost: $3,200,796 (USD; Tot_Drug_Cst)2020 Drug cost: $5,687,141 (USD; Tot_Drug_Cst)2021 Drug cost: $4,699,632 (USD; Tot_Drug_Cst)2022 Drug cost: $4,717,444 (USD; Tot_Drug_Cst)2023 Drug cost: $4,633,404 (USD; Tot_Drug_Cst)2024 Drug cost: $4,638,431 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151991,254$1,148,449
20162131,255$1,294,338
20172121,171$1,715,738
20182361,463$2,356,908
20192661,378$3,200,796
20203001,908$5,687,141
20212861,396$4,699,632
20222831,308$4,717,444
20233211,565$4,633,404
20244061,739$4,638,431

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$36K$72K2015 Medicare payment: $30,362 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $10,140 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $7,541 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $2,672 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $71,583 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $427 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $1,236 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R167$30,362
201624130$10,140
2017N/R50$7,541
2018N/R66$2,672
2019N/R191$71,583
2020N/R28$427
2021N/RN/RN/R
2022N/R26$1,236
2023N/RN/RN/R
2024N/RN/RN/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99223Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes133184$138
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more4121,288$94
99232Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes164596$63
36415Insertion of needle into vein for collection of blood sample3741,215$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count3711,289$7

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
BrukinsaZanubrutinib782,340$1,141,855
RevlimidLenalidomide431,106$657,545
ImbruvicaIbrutinib371,036$581,095
InlytaAxitinib28840$541,615
KisqaliRibociclib Succinate13364$220,251

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.26$513Novartis Pharmaceuticals Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Adli Yakan, MD?

Tedicare shows public-source Medicare data for Adli Yakan, MD (NPI 1417174699), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adli Yakan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adli Yakan, MD?

Adli Yakan, MD is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Adli Yakan, MD have Open Payments data?

Adli Yakan, MD has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.